Drug intelligence / Profile preview

T2309

Development stage: Preclinical
Lead developer: Théa Pharmaceuticals
Administration: Oral

Overview

T2309 is a Food for Special Medical Purpose developed by Laboratoires Thea. It is currently undergoing assessment for gastrointestinal tolerance, with a clinical trial involving 50 subjects. The product is administered orally as 4 capsules daily for 12 weeks.

Beyond the preview

Go deeper on T2309.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T2309.

Explore the full profile